Loading
GATA3 (Trans-acting T-cell-specific transcription factor GATA-3) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Non-Hodgkin lymphoma, Leukaemia and 2 more.
Transcriptional activator which binds to the enhancer of the T-cell receptor alpha and delta genes. Binds to the consensus sequence 5'-AGATAG-3'. Required for the T-helper 2 (Th2) differentiation process following immune and inflammatory responses.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Cobimetinib. Open Targets scores its association with cancer at 0.78 (direct and indirect evidence; datatypes affected pathway 0.56, literature 0.99, genetic association 0.37, somatic mutation 0.87, animal model 0.65). IntOGen calls it a driver in 7 cohorts (3 activating, 3 loss-of-function), covering Acute Lymphoblastic Leukaemia, Invasive Breast Carcinoma.
In plain words · GATA3 (Trans-acting T-cell-specific transcription factor GATA-3) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Non-Hodgkin lymphoma, Leukaemia and 2 more.
GATA3 (Trans-acting T-cell-specific transcription factor GATA-3) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Non-Hodgkin lymphoma, Leukaemia and 2 more.
Transcriptional activator which binds to the enhancer of the T-cell receptor alpha and delta genes. Binds to the consensus sequence 5'-AGATAG-3'.
No product in this corpus aims at GATA3 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA GATA3: RNA tissue enhanced (parathyroid gland 112 nTPM, skin 1 169 nTPM); blood lineage group enriched (NK-cells 40 nTPM, T-cells 51 nTPM); high antibody staining in 1 normal tissue; highest cancer staining breast cancer (3 of 9 high). Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Breast cancer (all types), Lymphoma, Leukaemia); Open Targets associates it with 4 specific cancer types at or above 0.5 (B-cell acute lymphoblastic leukemia, breast adenocarcinoma, Hodgkins lymphoma, nasal cavity polyp). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt P23771; CIViC gene GATA3; IntOGen GATA3; Human Protein Atlas GATA3 tissue; Open Targets ENSG00000107485 associations
First described 1991. Earliest sequence paper UniProt cites for the protein: Joulin et al, EMBO J, 1991, "A T-cell specific TCR delta DNA binding protein is a member of the human GATA family". Source.
Sources: HGNC HGNC:4172 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P23771 (protein name, function text, keywords and locations (REST API)); CIViC gene GATA3 (1 evidence items, 0 assertions, 1 variants; diseases: Histiocytosis-Lymphadenopathy Plus Syndrome (GraphQL API, CC0)); Open Targets ENSG00000107485 (association with cancer (MONDO_0004992) 0.78; per-cancer scores at or above 0.5: acute lymphoblastic leukaemia 0.62, Hodgkins lymphoma 0.51, non-Hodgkin lymphoma 0.66, breast cancer 0.74, leukaemia 0.66 (GraphQL API, CC0)); IntOGen GATA3 (driver in 7 cohorts (Act 3, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Transcriptional activator which binds to the enhancer of the T-cell receptor alpha and delta genes. Binds to the consensus sequence 5'-AGATAG-3'. Required for the T-helper 2 (Th2) differentiation process following immune and inflammatory responses. Positively regulates ASB2 expression. Coordinates macrophage transcriptional activation and UCP2-dependent metabolic reprogramming in response to IL33. Upon tissue injury, acts downstream of IL33 signalling to drive differentiation of inflammation-resolving alternatively activated macrophages. Location: Nucleus (UniProt). Locus 10p14 (HGNC).
RNA: tissue enhanced (parathyroid gland 112 nTPM, skin 1 169 nTPM), detected in many normal tissues. Blood: group enriched (NK-cells 40 nTPM, T-cells 51 nTPM).
Medium: Breast, Epididymis, Parathyroid gland, Placenta, Rectum, Seminal vesicle, Skin, Urinary bladder.
RNA group enriched: Bladder Urothelial Carcinoma 126 pTPM, Breast Invasive Carcinoma 330 pTPM.
Medium only: colorectal cancer, liver cancer, ovarian cancer, pancreatic cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"GATA3" OR ABSTRACT:"GATA3" OR TITLE:"GATA binding protein 3" OR ABSTRACT:"GATA binding protein 3" OR TITLE:"Trans-acting T-cell-specific transcription factor GATA-3" OR ABSTRACT:"Trans-acting T-cell-specific transcription factor GATA-3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GATA3, not a curated reading list.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, CIViC, Breast cancer (all types).
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, CIViC, IntOGen.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, IntOGen, Breast cancer (all types).
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, CIViC, IntOGen.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, CIViC, IntOGen.
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, IntOGen, Non-Hodgkin lymphoma (all types).
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, IntOGen, Non-Hodgkin lymphoma (all types).
Shares Leukaemia (all types), Acute lymphoblastic leukaemia, CIViC, IntOGen.